Engineered immune cells take aim at lupus and MS
NCT ID NCT06775912
First seen Feb 02, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune responses in autoimmune diseases like lupus, scleroderma, and multiple sclerosis. The main goal is to check safety and how the body handles the therapy in 18 adults aged 18 to 70. It is not a cure, but aims to control disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First People's Hospital of Lianyungang
RECRUITINGLianyungang, Jiangus, 222000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.